HR Execs on the Move

OptimizeRx

www.optimizerx.com

 
OptimizeRx® (OPRX) provides unique physician and consumer platforms and strategies to help patients better afford and adhere to their treatment regimens, while offering pharmaceutical and healthcare companies more effective ways to deliver relevant information and services to healthcare providers and their patients right at the point of care.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.optimizerx.com
  • 400 Water Street Suite 200
    Rochester, MI USA 48307
  • Phone: 248.651.6568

Executives

Name Title Contact Details
Doug Besch
SVP Product Strategy & Innovation Profile
Karen Lauer
Vice President Of Product Development Profile
Michael Rousselle
VP Data Product Profile
Dan Marsh
VP of Sales Profile
Edward Stelmakh
Chief Financial Officer and Chief Operating Officer Profile

Similar Companies

Sanford Applied Biosciences

Hematech, Inc was founded in 1998, with corporate headquarters in Sioux Falls, SD. Hematech is a subsidiary of Kyowa Hakko Kirin Company, Ltd. In 2002, Hematech and Kirin consolidated their transgenic bovine research programs in facilities in Sioux

Mason City Clinic

The Mason City Clinic was formed on January 1, 1989, with the merger of three physician groups -- Surgical Associates, Internal Medicine Associates and Independent Medical Surgical Group.

Ardian

Ardian is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurostream Technologies

Neurostream Technologies is a Saint-Augustin-De-Desmaures, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.